Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Kulagin, Alexander  [Clear All Filters]
Journal Article
Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, Gulbas Z, Martin JDiez, Araujo MColorado, Kulagin A, et al. Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transplant. 2022.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):106.
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, et al. Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol. 2024;15:1350470.
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.
Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood. 2022.
Nagler A, Labopin M, Swoboda R, Kulagin A, Velardi A, Sanz J, Labussière-Wallet H, Potter V, Kuball J, Sica S, et al. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marr. Bone Marrow Transplant. 2023.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):58.
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griškevičius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation. Bone Marrow Transplant. 2024.
Griffin M, Eikema D-J, Verheggen I, Kulagin A, Tjon JM-L, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, et al. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria. Haematologica. 2023.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PPal, Versluis J, Rovira M, Blaise D, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT. Blood. 2024.